Alexa B. Kimball

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

Medicine, Dermatology, Immunology +15

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Alan Menter, Stephen K. Tyring, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology · 2007 · 883 citations

Life Sciences, Dermatology, Immunology +10

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2017 · 860 citations · Full text

Medicine, Dermatology, Pharmacotherapy +17

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

Mark Lebwohl, Bruce Strober, Alan Menter et al. · New England Journal of Medicine · 2015 · 806 citations · Full text

Medicine, Dermatology, Pharmacotherapy +10

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball, Martin M. Okun, David Williams et al. · New England Journal of Medicine · 2016 · 777 citations

Medicine, Dermatology, Pharmacology +16